Want to see ARMP full AI Analyst Report?
Armata Pharmaceuticals (ARMP) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ap-Pa02 | Pseudomonas Aeruginosa, Lung Infection, Non-Cystic Fibrosis Bronchiectasis | Phase II | Completed | Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection | Nov 07, 2022 | ― |
| Ap-Sa02 | Staphylococcus Aureus, Bacteremia, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due To Staphylococcus Aureus | phase1AndPhase2 | Completed | Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia | Nov 24, 2021 | ― |
| Ap-Pa02 | Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal | phase1AndPhase2 | Completed | Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis | Oct 15, 2020 | ― |
| C16g2 | Dental Caries | Phase II | Completed | A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects | Jun 21, 2017 | ― |
| C16g2 Strip | Dental Caries | Phase II | Completed | A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application | Feb 10, 2017 | ― |
| C16g2 Varnish | Dental Caries | Phase II | Completed | A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects | Dec 16, 2016 | ― |
| Ab-Sa01 (10^8 Pfu Per Phage), Ab-Sa01 (10^9 Pfu Per Phage) | Healthy Volunteers | Phase I | Completed | Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults | Apr 27, 2016 | ― |
| C16g2 Gel | Dental Caries | Phase II | Completed | Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects | Oct 28, 2015 | ― |
| C16g2 | Dental Caries | Phase II | Completed | Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects | Jul 01, 2015 | ― |
| C16g2 | Dental Caries | Phase II | Completed | Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses | Sep 24, 2014 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ap-Pa02 | Phase II | Pseudomonas Aeruginosa, Lung Infection, Non-Cystic Fibrosis Bronchiectasis | Completed | Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection | Nov 07, 2022 | ― |
| Ap-Sa02 | phase1AndPhase2 | Staphylococcus Aureus, Bacteremia, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due To Staphylococcus Aureus | Completed | Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia | Nov 24, 2021 | ― |
| Ap-Pa02 | phase1AndPhase2 | Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal | Completed | Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis | Oct 15, 2020 | ― |
| C16g2 | Phase II | Dental Caries | Completed | A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects | Jun 21, 2017 | ― |
| C16g2 Strip | Phase II | Dental Caries | Completed | A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application | Feb 10, 2017 | ― |
| C16g2 Varnish | Phase II | Dental Caries | Completed | A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects | Dec 16, 2016 | ― |
| Ab-Sa01 (10^8 Pfu Per Phage), Ab-Sa01 (10^9 Pfu Per Phage) | Phase I | Healthy Volunteers | Completed | Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults | Apr 27, 2016 | ― |
| C16g2 Gel | Phase II | Dental Caries | Completed | Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects | Oct 28, 2015 | ― |
| C16g2 | Phase II | Dental Caries | Completed | Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects | Jul 01, 2015 | ― |
| C16g2 | Phase II | Dental Caries | Completed | Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses | Sep 24, 2014 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Armata Pharmaceuticals Inc (ARMP) have in its pipeline
Armata Pharmaceuticals ARMP is currently developing the following drugs: Ap-Pa02, Ap-Sa02, C16g2, C16g2 Strip, C16g2 Varnish, Ab-Sa01 (10^8 Pfu Per Phage), Ab-Sa01 (10^9 Pfu Per Phage), C16g2 Gel, C16g2 Rinse, C16g2 Gel. These drug candidates are in various stages of clinical development as the company works toward FDA approval.